OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.
The company believes that better and earlier detection of cancer through liquid biopsies will:
Current diagnostic standards fall short by many measures. At present, diagnostic tests for cancer rely on scans and then tissue samples from invasive surgical procedures to determine if a tumor is benign or malignant.
These invasive tests are expensive, time-consuming when time may be of utmost importance, and lead to both patient anxiety and physician uncertainty about the diagnosis.
Our next generation liquid biopsy diagnostics will use blood or urine samples to detect the presence or absence of cancer. These diagnostics are:
OncoCyte’s initial focus is on cancers with large patient populations and significant unmet need.
|Employees (est.) (Feb 2019)||16|
|Share Price (Mar 2019)||$3.6||(-2%)|
Net income (Q2, 2018)
EBIT (Q2, 2018)
Market capitalization (21-Mar-2019)
Closing stock price (21-Mar-2019)
Patents and Patent Applications
Who are OncoCyte key executives?
OncoCyte's key executives are William Annett, Lyssa Friedman and Lyndal Hesterberg.
How many employees does OncoCyte have?
OncoCyte has 16 employees.
Who are OncoCyte competitors?
Competitors of OncoCyte include Thriva, hVIVO and Immucor.
Where is OncoCyte headquarters?
OncoCyte headquarters is located at 1010 Atlantic Ave #102, Alameda.
Where are OncoCyte offices?
OncoCyte has an office in Alameda.
How many offices does OncoCyte have?
OncoCyte has 1 office.